Therapeutic responses to different anti-Trypanosoma cruzi drugs in experimental infection by benznidazole-resistant parasite stock.

Simple item page
dc.contributor.authorCaldas, Sérgio
dc.contributor.authorCaldas, Ivo Santana
dc.contributor.authorCecílio, Alzira Batista
dc.contributor.authorDiniz, Lívia de Figueiredo
dc.contributor.authorSilva, André Talvani Pedrosa da
dc.contributor.authorRibeiro, Isabela
dc.contributor.authorBahia, Maria Terezinha
dc.date.accessioned2017-05-31T17:11:51Z
dc.date.available2017-05-31T17:11:51Z
dc.date.issued2014
dc.description.abstractupon mice infection with a benznidazole-resistant Trypanosoma cruzi strain in the pathological outcomes. Trypanosoma cruzi-infected mice were treated with different drugs and parasite clearance time was detected by blood and tissue qPCR, to determine the dynamic relationship between the efficacy of the treatments and the intensity of heart lesion/serum inflammatory mediators. Our results indicate that anti-T. cruzi treatments were able to reduce parasite replication and consequently induce immunomodulatory effects, where the degree of the immunopathology prevention was related to the time of parasite clearance induced by different treatments. Nevertheless, in benznidazole and posaconazole treatments, parasite rebounding was detected with parasitism reaching levels similar to infected and non-treated mice; the time for parasitic rebound being earlier among benznidazole-treated mice. In parallel, an increase of cardiac lesions and plasma chemokine levels was also detected and was more accentuated in benznidazole-treated animals. Interestingly, in the presence of parasitological cure (fexinidazole treatment), basal levels of these inflammatory mediators were evidenced as well as an absence of cardiac inflammation or fibrosis. Overall, our data indicate that all treatments have positive effects on the clinical evolution of T. cruzi infection, with success in preventing cardiac alterations being drug-dependent.pt_BR
dc.identifier.citationCALDAS, S. et al. Therapeutic responses to different anti-Trypanosoma cruzi drugs in experimental infection by benznidazole-resistant parasite stock. Parasitology, v. 141, p. 1628-1637, 2014. Disponível em: <https://goo.gl/oNhl1T>. Acesso em: 19 fev. 2017.pt_BR
dc.identifier.doihttps://doi.org/10.1017/S0031182014000882
dc.identifier.issn1469-8161
dc.identifier.urihttp://www.repositorio.ufop.br/handle/123456789/7841
dc.identifier.uri2https://goo.gl/oNhl1Tpt_BR
dc.language.isoen_USpt_BR
dc.rightsrestritopt_BR
dc.subjectChemotherapypt_BR
dc.subjectInflammationpt_BR
dc.subjectPosaconazolept_BR
dc.subjectFexinidazolept_BR
dc.titleTherapeutic responses to different anti-Trypanosoma cruzi drugs in experimental infection by benznidazole-resistant parasite stock.pt_BR
dc.typeArtigo publicado em periodicopt_BR
Files
Collections
DECBI - Artigos publicados em periódicos